, /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, announces the acceptance for publication of a research article entitled "Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics and Safety Characteristics in Göttingen Minipigs and Rabbits" in the esteemed journal Precision Nanomedicine.
The study demonstrates promising results of prolonged release and a favorable safety profile of CBD following a single subcutaneous administration of LPT-CBD in minipigs.
Corporate Updates
Resignation of Director and Executive Chairman
Ron Mayron has resigned as Executive Chairman and a Director of the Company effective July 1, 2025. Mr. Mayron will remain with the Company for three additional months as a Special Consultant for the Company. In his place, Iris Bincovich, a current Director of the Company, will be temporarily holding the position of Chair of the Company.
Iris Bincovich, Chief Executive Officer and Chair of the Company stated "we are grateful to Ron, one of the Company's founders, for his meaningful contributions over the past several years. His dedication and leadership have been greatly appreciated. We wish Ron the best of luck in his future endeavors."
Grants of RSU's and Stock Options
On July 2, 2025, the Company granted an aggregate of 23,050,000 Restricted Share Units ("RSUs") to certain directors, officers, employees and consultants of the Company, payable in common shares of the Company upon satisfaction of various milestone-based vesting conditions. On July 2, 2025, the Company also granted an aggregate of 1,950,000 stock options of the Company (the "Options") at an exercise price of $0.225 with a five-year expiry date to various employees of the Company. The RSUs and the Options were granted under the Company's stock option plan as most recently amended on June 26, 2025. All RSU's, Options and underlying common shares are subject to a hold period of four months and one day pursuant to the policies of the Canadian Securities Exchange.
About Innocan
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. www.innocanpharma.com
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo - https://mma.prnewswire.com/media/2570689/5400283/Innocan_Pharma_Logo.jpg
SOURCE Innocan Pharma Corporation
